Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2026

Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview

• Ribose-Nucleic Acid (RNA)-Based Therapeutics market size has reached to $17.22 billion in 2025 • Expected to grow to $26.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Increasing Prevalence Of Cancer On The RNA-Based Therapeutics Market • Market Trend: Advancements In RNA-Based Therapeutics With mRNA-Based Vaccines • North America was the largest region in 2025.

What Is Covered Under Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

The ribose-nucleic acid (RNA)-based therapeutics refer to a class of medical treatments that utilize ribose-nucleic acid (RNA) molecules to influence cellular processes, typically by targeting specific genetic sequences. These therapies are designed to treat various conditions, including genetic disorders, cancers, and infectious diseases, by modulating gene expression, protein production, or cellular signaling pathways. The main types of ribose-nucleic acid (RNA)-based therapeutics are RNA interference (RNAi) and RNA antisense. RNA interference (RNAi) is a biological process where RNA molecules inhibit gene expression or translation by neutralizing targeted mRNA molecules. The various technologies include enabling technology. It is used for varying therapeutic areas such as oncology, genetic disorders, ophthalmology, hematological disorders, acute hepatic porphyria (AHP), and others by different end users, including research institutes, hospitals, and clinics.

What Is The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Growth Forecast?

The ribose-nucleic acid (rna)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $26.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, rising demand for personalized medicine, expansion of oncology-focused rna pipelines, growing investments in delivery technologies, increasing collaborations between biotech firms. Major trends in the forecast period include increasing development of rna-based targeted therapies, rising use of sirna and aso technologies, growing focus on rare and genetic disorders, expansion of clinical trials for rna therapeutics, enhanced drug delivery system innovations.

Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Segmentation

1) By Type: RNA Interference (RNAi), RNA Antisense 2) By Technology: Enabling Technology, Enabled Technology 3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas 4) By End User: Research Institutes, Hospitals And Clinics Subsegments: 1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA) 2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

What Is The Driver Of The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

The increasing prevalence of cancer is expected to propel the growth of the ribose-nucleic acid (RNA)-based therapeutics market going forward. Cancer refers to a condition where abnormal cells grow and spread uncontrollably, potentially leading to death if untreated. The prevalence of cancer is due to an aging population, lifestyle changes, greater exposure to risks, and better detection methods. RNA-based therapeutics offer a promising avenue for cancer treatment by directly targeting the genetic and molecular mechanisms of cancer. For instance, in August 2023, according to the Australian Institute of Health and Welfare, an Australia-based government administration for health, around 151,000 individuals were diagnosed with cancer (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021, which is expected to reach 185,000 in 2030. Therefore, the increasing prevalence of cancer is driving the ribose-nucleic acid (RNA)-based therapeutics industry.

Key Players In The Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

Major companies operating in the ribose-nucleic acid (rna)-based therapeutics market are F Hoffmann La Roche AG, Eli Lilly And Company, Novo Nordisk AS, Regeneron Pharmaceuticals, Biogen Inc., BioNTech, Alnylam Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics, Moderna Inc., CureVac NV, Silence Therapeutics plc, ProQR Therapeutics NV

Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Trends and Insights

Major companies operating in the ribose nucleic acid (RNA)-based therapeutics market are focused on developing innovative medication solutions, such as messenger RNA (mRNA)-based booster vaccines, to enhance the effectiveness of immunization, address emerging viral variants, and improve the overall durability of vaccine-induced immunity. An mRNA-based booster vaccine uses messenger RNA to prompt cells to create a protein that enhances the body's immune response against a particular pathogen. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, launched GEMCOVAC-OM, India's first mRNA booster vaccine specifically targeting the Omicron variant of COVID-19. This booster is essential due to the limited efficacy of the original vaccines against Omicron. Utilizing mRNA technology, GEMCOVAC-OM boosts immunity and offers enhanced protection against the evolving virus.

What Are Latest Mergers And Acquisitions In The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

In May 2024, Orna Therapeutics, a US-based biotechnology company focusing on developing RNA-based therapeutics, acquired ReNAgade Therapeutics for an undisclosed amount. Through this acquisition, Orna seeks to enhance its industry-leading strategy by merging its circular RNA expression technology with ReNAgade's extensive LNP-based RNA delivery systems and editing programs. ReNAgade Therapeutics is a US-based biotechnology company specializing in RNA-based therapeutics.

Regional Outlook

North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

The ribose-nucleic acid (RNA)-based therapeutics market consists of revenues earned by entities by custom synthesis of RNA, RNA delivery systems, and RNA sequencing analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribose-nucleic acid (RNA)-based therapeutics market also includes the sale of microRNA (miRNA) therapeutics, antisense oligonucleotides, and messenger RNA (mRNA) vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2026?

The ribose-nucleic acid (rna)-based therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribose-nucleic acid (rna)-based therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.